AMD3100 ameliorates cigarette smoke-induced emphysema-like manifestations in mice

Daria Barwinska, Houssam Oueini, Christophe Poirier, Marjorie E. Albrecht, Natalia Bogatcheva, Matthew J. Justice, Jacob Saliba, Kelly S. Schweitzer, Hal Broxmeyer, Keith L. March, Irina Petrache

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

We have shown that cigarette smoke (CS)-induced pulmonary emphysema-like manifestations are preceded by marked suppression of the number and function of bone marrow hematopoietic progenitor cells (HPCs). To investigate whether a limited availability of HPCs may contribute to CS-induced lung injury, we used a Food and Drug Administration-approved antagonist of the interactions of stromal cell-derived factor 1 (SDF-1) with its chemokine receptor CXCR4 to promote intermittent HPC mobilization and tested its ability to limit emphysema-like injury following chronic CS. We administered AMD3100 (5mg/kg) to mice during a chronic CS exposure protocol of up to 24 wk. AMD3100 treatment did not affect either lung SDF-1 levels, which were reduced by CS, or lung inflammatory cell counts. However, AMD3100 markedly improved CS-induced bone marrow HPC suppression and significantly ameliorated emphysema-like end points, such as alveolar airspace size, lung volumes, and lung static compliance. These results suggest that antagonism of SDF-1 binding to CXCR4 is associated with protection of both bone marrow and lungs during chronic CS exposure, thus encouraging future studies of potential therapeutic benefit of AMD3100 in emphysema.

Original languageEnglish (US)
Pages (from-to)L382-L386
JournalAmerican Journal of Physiology - Lung Cellular and Molecular Physiology
Volume315
Issue number3
DOIs
StatePublished - Sep 1 2018

Fingerprint

Emphysema
Smoke
Tobacco Products
Hematopoietic Stem Cells
Chemokine CXCL12
Lung
Bone Marrow
Lung Compliance
Pulmonary Emphysema
Chemokine Receptors
Lung Injury
United States Food and Drug Administration
JM 3100
Cell Count
Wounds and Injuries

Keywords

  • Bone marrow
  • COPD
  • Emphysema
  • Lung treatment

ASJC Scopus subject areas

  • Physiology
  • Pulmonary and Respiratory Medicine
  • Physiology (medical)
  • Cell Biology

Cite this

AMD3100 ameliorates cigarette smoke-induced emphysema-like manifestations in mice. / Barwinska, Daria; Oueini, Houssam; Poirier, Christophe; Albrecht, Marjorie E.; Bogatcheva, Natalia; Justice, Matthew J.; Saliba, Jacob; Schweitzer, Kelly S.; Broxmeyer, Hal; March, Keith L.; Petrache, Irina.

In: American Journal of Physiology - Lung Cellular and Molecular Physiology, Vol. 315, No. 3, 01.09.2018, p. L382-L386.

Research output: Contribution to journalArticle

Barwinska, Daria ; Oueini, Houssam ; Poirier, Christophe ; Albrecht, Marjorie E. ; Bogatcheva, Natalia ; Justice, Matthew J. ; Saliba, Jacob ; Schweitzer, Kelly S. ; Broxmeyer, Hal ; March, Keith L. ; Petrache, Irina. / AMD3100 ameliorates cigarette smoke-induced emphysema-like manifestations in mice. In: American Journal of Physiology - Lung Cellular and Molecular Physiology. 2018 ; Vol. 315, No. 3. pp. L382-L386.
@article{fb65ee23b69e4d7b91e1e5d637fadc2f,
title = "AMD3100 ameliorates cigarette smoke-induced emphysema-like manifestations in mice",
abstract = "We have shown that cigarette smoke (CS)-induced pulmonary emphysema-like manifestations are preceded by marked suppression of the number and function of bone marrow hematopoietic progenitor cells (HPCs). To investigate whether a limited availability of HPCs may contribute to CS-induced lung injury, we used a Food and Drug Administration-approved antagonist of the interactions of stromal cell-derived factor 1 (SDF-1) with its chemokine receptor CXCR4 to promote intermittent HPC mobilization and tested its ability to limit emphysema-like injury following chronic CS. We administered AMD3100 (5mg/kg) to mice during a chronic CS exposure protocol of up to 24 wk. AMD3100 treatment did not affect either lung SDF-1 levels, which were reduced by CS, or lung inflammatory cell counts. However, AMD3100 markedly improved CS-induced bone marrow HPC suppression and significantly ameliorated emphysema-like end points, such as alveolar airspace size, lung volumes, and lung static compliance. These results suggest that antagonism of SDF-1 binding to CXCR4 is associated with protection of both bone marrow and lungs during chronic CS exposure, thus encouraging future studies of potential therapeutic benefit of AMD3100 in emphysema.",
keywords = "Bone marrow, COPD, Emphysema, Lung treatment",
author = "Daria Barwinska and Houssam Oueini and Christophe Poirier and Albrecht, {Marjorie E.} and Natalia Bogatcheva and Justice, {Matthew J.} and Jacob Saliba and Schweitzer, {Kelly S.} and Hal Broxmeyer and March, {Keith L.} and Irina Petrache",
year = "2018",
month = "9",
day = "1",
doi = "10.1152/ajplung.00185.2018",
language = "English (US)",
volume = "315",
pages = "L382--L386",
journal = "American Journal of Physiology",
issn = "1040-0605",
publisher = "American Physiological Society",
number = "3",

}

TY - JOUR

T1 - AMD3100 ameliorates cigarette smoke-induced emphysema-like manifestations in mice

AU - Barwinska, Daria

AU - Oueini, Houssam

AU - Poirier, Christophe

AU - Albrecht, Marjorie E.

AU - Bogatcheva, Natalia

AU - Justice, Matthew J.

AU - Saliba, Jacob

AU - Schweitzer, Kelly S.

AU - Broxmeyer, Hal

AU - March, Keith L.

AU - Petrache, Irina

PY - 2018/9/1

Y1 - 2018/9/1

N2 - We have shown that cigarette smoke (CS)-induced pulmonary emphysema-like manifestations are preceded by marked suppression of the number and function of bone marrow hematopoietic progenitor cells (HPCs). To investigate whether a limited availability of HPCs may contribute to CS-induced lung injury, we used a Food and Drug Administration-approved antagonist of the interactions of stromal cell-derived factor 1 (SDF-1) with its chemokine receptor CXCR4 to promote intermittent HPC mobilization and tested its ability to limit emphysema-like injury following chronic CS. We administered AMD3100 (5mg/kg) to mice during a chronic CS exposure protocol of up to 24 wk. AMD3100 treatment did not affect either lung SDF-1 levels, which were reduced by CS, or lung inflammatory cell counts. However, AMD3100 markedly improved CS-induced bone marrow HPC suppression and significantly ameliorated emphysema-like end points, such as alveolar airspace size, lung volumes, and lung static compliance. These results suggest that antagonism of SDF-1 binding to CXCR4 is associated with protection of both bone marrow and lungs during chronic CS exposure, thus encouraging future studies of potential therapeutic benefit of AMD3100 in emphysema.

AB - We have shown that cigarette smoke (CS)-induced pulmonary emphysema-like manifestations are preceded by marked suppression of the number and function of bone marrow hematopoietic progenitor cells (HPCs). To investigate whether a limited availability of HPCs may contribute to CS-induced lung injury, we used a Food and Drug Administration-approved antagonist of the interactions of stromal cell-derived factor 1 (SDF-1) with its chemokine receptor CXCR4 to promote intermittent HPC mobilization and tested its ability to limit emphysema-like injury following chronic CS. We administered AMD3100 (5mg/kg) to mice during a chronic CS exposure protocol of up to 24 wk. AMD3100 treatment did not affect either lung SDF-1 levels, which were reduced by CS, or lung inflammatory cell counts. However, AMD3100 markedly improved CS-induced bone marrow HPC suppression and significantly ameliorated emphysema-like end points, such as alveolar airspace size, lung volumes, and lung static compliance. These results suggest that antagonism of SDF-1 binding to CXCR4 is associated with protection of both bone marrow and lungs during chronic CS exposure, thus encouraging future studies of potential therapeutic benefit of AMD3100 in emphysema.

KW - Bone marrow

KW - COPD

KW - Emphysema

KW - Lung treatment

UR - http://www.scopus.com/inward/record.url?scp=85053360735&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053360735&partnerID=8YFLogxK

U2 - 10.1152/ajplung.00185.2018

DO - 10.1152/ajplung.00185.2018

M3 - Article

C2 - 29745251

AN - SCOPUS:85053360735

VL - 315

SP - L382-L386

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 1040-0605

IS - 3

ER -